SEARCH

SEARCH BY CITATION

References

  • 1
    Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R, et al. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 2001; 32: 492497.
  • 2
    Weber R, Sabin CA, Friis-Moller N, Reiss P, El-Sadr WM, Kirk O, et al. Liver-related deaths in persons infected with the human immunodeficiency virus: the D:A:D study. Arch Intern Med 2006; 166: 16321641.
  • 3
    World Health Organization. Available at: http://www.who.int/topics/hiv_infections/en/. Accessed March 20, 2007.
  • 4
    Alter MJ. Epidemiology of viral hepatitis and HIV co-infection. J Hepatol 2006; 44: S6S9.
  • 5
    Luetkemeyer A, Hare CB, Stansell J, Tien PC, Charlesbois E, Lum P, et al. Clinical presentation and course of acute hepatitis C infection in HIV-infected patients. J Acquir Immune Defic Syndr 2006; 41: 3136.
  • 6
    Serpaggi J, Chaix ML, Batisse D, Dupont C, Vallet-Pichard A, Fontaine H, et al. Sexually transmitted acute infection with a clustered genotype 4 hepatitis C virus in HIV-1-infected men and inefficacy of early antiviral therapy. AIDS 2006; 20: 233240.
  • 7
    Brau N, Salvatore M, Rios-Bedoya CF, Fernandez-Carbia A, Paronetto F, Rodriguez-Orengo JF, et al. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 2006; 44: 4755.
  • 8
    Graham C, Wells A, Murray J, Heeren T, Timilty S, Stuver S, et al. The impact of alcohol and HIV on antigen-specific immune responses in hepatitis C. J Infect Dis. In press.
  • 9
    Koziel MJ. Influence of HIV co-infection on hepatitis C immunopathogenesis. J Hepatol 2006; 44: S14S18.
  • 10
    Gale M Jr, Foy EM. Evasion of intracellular host defence by hepatitis C virus. Nature 2005; 436: 939945.
  • 11
    Komatsu H, Lauer G, Pybus OG, Ouchi K, Wong D, Ward S, et al. Do antiviral CD8+ T cells select hepatitis C virus escape mutants? Analysis in diverse epitopes targeted by human intrahepatic CD8+ T lymphocytes. J Viral Hepat 2006; 13: 121130.
  • 12
    Grakoui A, Shoukry NH, Woollard DJ, Han JH, Hanson HL, Ghrayeb J, et al. HCV persistence and immune evasion in the absence of memory T cell help. Science 2003; 302: 659662.
  • 13
    Erickson AL, Kimura Y, Igarashi S, Eichelberger J, Houghton M, Sidney J, et al. The outcome of hepatitis C virus infection is predicted by escape mutations in epitopes targeted by cytotoxic T lymphocytes. Immunity 2001; 15: 883895.
  • 14
    Weiner A, Erickson AL, Kansopon J, Crawford K, Muchmore E, Hughes AL, et al. Persistent hepatitis C virus infection in a chimpanzee is associated with emergence of a cytotoxic T lymphocyte escape variant. Proc Natl Acad Sci U S A 1995; 92: 27552759.
  • 15
    Weiner AJ, Erickson AL, Kansopon J, Crawford K, Muchmore E, Houghton M, et al. Association of cytotoxic T lymphocyte (CTL) escape mutations with persistent hepatitis C virus (HCV) infection. Princess Takamatsu Symp 1995; 25: 227235.
  • 16
    Gruener NH, Lechner F, Jung MC, Diepolder H, Gerlach T, Lauer G, et al. Sustained dysfunction of antiviral CD8+ T lymphocytes after infection with hepatitis C virus. J Virol 2001; 75: 55505558.
  • 17
    Semmo N, Day CL, Ward SM, Lucas M, Harcourt G, Loughry A, et al. Preferential loss of IL-2-secreting CD4+ T helper cells in chronic HCV infection. HEPATOLOGY 2005; 41: 10191028.
  • 18
    Spangenberg HC, Viazov S, Kersting N, Neumann-Haefelin C, McKinney D, Roggendorf M, et al. Intrahepatic CD8+ T-cell failure during chronic hepatitis C virus infection. HEPATOLOGY 2005; 42: 828837.
  • 19
    Anthony DD, Yonkers NL, Post AB, Asaad R, Heinzel FP, Lederman MM, et al. Selective impairments in dendritic cell-associated function distinguish hepatitis C virus and HIV infection. J Immunol 2004; 172: 49074916.
  • 20
    Graham CS, Wells A, Liu T, Sherman KE, Peters M, Chung RT, et al. Antigen-specific immune responses and liver histology in HIV and hepatitis C coinfection. AIDS 2005; 19: 767773.
  • 21
    Kamal SM, Graham CS, He Q, Bianchi L, Tawil AA, Rasenack JW, et al. Kinetics of intrahepatic hepatitis C virus (HCV)-specific CD4+ T cell responses in HCV and Schistosoma mansoni coinfection: relation to progression of liver fibrosis. J Infect Dis 2004; 189: 11401150.
  • 22
    Graham CS, Wells A, Liu T, Sherman KE, Peters M, Chung RT, et al. Relationships between cellular immune responses and treatment outcomes with interferon and ribavirin in HIV/hepatitis C virus co-infection. AIDS 2006; 20: 345351.
  • 23
    Ramos B, Nunez M, Martin-Carbonero L, Sheldon J, Rios P, Labarga P, et al. Hepatitis B virus genotypes and lamivudine resistance mutations in HIV/hepatitis B virus-coinfected patients. J Acquir Immune Defic Syndr 2007.
  • 24
    Munshi N, Balasubramanian A, Koziel M, Ganju RK, Groopman JE. Hepatitis C and human immunodeficiency virus envelope proteins cooperatively induce hepatocytic apoptosis via an innocent bystander mechanism. J Infect Dis 2003; 188: 11921204.
  • 25
    Balasubramanian A, Ganju RK, Groopman JE. Signal transducer and activator of transcription factor 1 mediates apoptosis induced by hepatitis C virus and HIV envelope proteins in hepatocytes. J Infect Dis 2006; 194: 670681.
  • 26
    Vlahakis SR, Villasis-Keever A, Gomez TS, Bren GD, Paya CV. Human immunodeficiency virus-induced apoptosis of human hepatocytes via CXCR4. J Infect Dis 2003; 188: 14551460.
  • 27
    Gerschenson M, Nguyen VT, St Claire MC, Harbaugh SW, Harbaugh JW, Proia LA, et al. Chronic stavudine exposure induces hepatic mitochondrial toxicity in adult Erythrocebus patas monkeys. J Hum Virol 2001; 4: 335342.
  • 28
    Birkus G, Hitchcock MJ, Cihlar T. Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparison with other nucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 2002; 46: 716723.
  • 29
    Gerschenson M, Brinkman K. Mitochondrial dysfunction in AIDS and its treatment. Mitochondrion 2004; 4: 763777.
  • 30
    Begriche K, Igoudjil A, Pessayre D, Fromenty B. Mitochondrial dysfunction in NASH: causes, consequences and possible means to prevent it. Mitochondrion 2006; 6: 128.
  • 31
    Domitrovich AM, Felmlee DJ, Siddiqui A. Hepatitis C virus nonstructural proteins inhibit apolipoprotein B100 secretion. J Biol Chem 2005; 280: 3980239808.
  • 32
    Kapadia SB, Chisari FV. Hepatitis C virus RNA replication is regulated by host geranylgeranylation and fatty acids. Proc Natl Acad Sci U S A 2005; 102: 25612566.
  • 33
    Dharancy S, Malapel M, Perlemuter G, Roskams T, Cheng Y, Dubuquoy L, et al. Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection. Gastroenterology 2005; 128: 334342.
  • 34
    Otake K, Omoto S, Yamamoto T, Okuyama H, Okada H, Okada N, et al. HIV-1 Nef protein in the nucleus influences adipogenesis as well as viral transcription through the peroxisome proliferator-activated receptors. AIDS 2004; 18: 189198.
  • 35
    de Mendoza C, Soriano V. The role of hepatitis C virus (HCV) in mitochondrial DNA damage in HIV/HCV-coinfected individuals. Antivir Ther 2005; 10( suppl 2): M109M115.
  • 36
    Benson CA, Kaplan JE, Masur H, Pau A, Holmes KK. Treating opportunistic infections among HIV-exposed and infected children. MMWR Recomm Rep 2004; 53: 1112.
  • 37
    Soriano V, Miro JM, Garcia-Samaniego J, Torre-Cisneros J, Nunez M, del Romero J, et al. Consensus conference on chronic viral hepatitis and HIV infection: updated Spanish recommendations. J Viral Hepat 2004; 11: 217.
  • 38
    Sherman KE, Rouster SD, Chung RT, Rajicic N. Hepatitis C virus prevalence among patients infected with human immunodeficiency virus: a cross-sectional analysis of the US Adult AIDS Clinical Trials Group. Clin Infect Dis 2002; 34: 831837.
  • 39
    Bonacini M, Lin HJ, Hollinger FB. Effect of coexisting HIV-1 infection on the diagnosis and evaluation of hepatitis C virus. J Acquir Immune Defic Syndr 2001; 26: 340344.
  • 40
    George SL, Gebhardt J, Klinzman D, Foster MB, Patrick KD, Schmidt WN, et al. Hepatitis C virus viremia in HIV-infected individuals with negative HCV antibody tests. J Acquir Immune Defic Syndr 2002; 31: 154162.
  • 41
    Amor A, Toro C, Jimenez V, Simon A, Ramos B, Soriano V. Seroreversion of HIV antibodies in patients with prolonged suppression of viraemia under HAART. AIDS 2006; 20: 14601462.
  • 42
    Sherman KE, O'Brien J, Gutierrez AG, Harrison S, Urdea M, Neuwald P, et al. Quantitative evaluation of hepatitis C virus RNA in patients with concurrent human immunodeficiency virus infections. J Clin Microbiol 1993; 31: 26792682.
  • 43
    Sherman KE, Rouster SD, Horn PS. Comparison of methodologies for quantification of hepatitis C virus (HCV) RNA in patients coinfected with HCV and human immunodeficiency virus. Clin Infect Dis 2002; 35: 482487.
  • 44
    Bonacini M, Govindarajan S, Blatt LM, Schmid P, Conrad A, Lindsay KL. Patients co-infected with human immunodeficiency virus and hepatitis C virus demonstrate higher levels of hepatic HCV RNA. J Viral Hepat 1999; 6: 203208.
  • 45
    Ragni MV, Bontempo FA. Increase in hepatitis C virus load in hemophiliacs during treatment with highly active antiretroviral therapy. J Infect Dis 1999; 180: 20272029.
  • 46
    Chung RT, Evans SR, Yang Y, Theodore D, Valdez H, Clark R, et al. Immune recovery is associated with persistent rise in hepatitis C virus RNA, infrequent liver test flares, and is not impaired by hepatitis C virus in co-infected subjects. AIDS 2002; 16: 19151923.
  • 47
    Sherman KE, Shire NJ, Cernohous P, Rouster SD, Omachi JH, Brun S, et al. Liver injury and changes in hepatitis C virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir. Clin Infect Dis 2005; 41: 11861195.
  • 48
    Overton ET, Sungkanuparph S, Powderly WG, Seyfried W, Groger RK, Aberg JA. Undetectable plasma HIV RNA load predicts success after hepatitis B vaccination in HIV-infected persons. Clin Infect Dis 2005; 41: 10451048.
  • 49
    Cooper CL, Davis HL, Angel JB, Morris ML, Elfer SM, Seguin I, et al. CPG 7909 adjuvant improves hepatitis B virus vaccine seroprotection in antiretroviral-treated HIV-infected adults. AIDS 2005; 19: 14731479.
  • 50
    Shire NJ, Rouster SD, Rajicic N, Sherman KE. Occult hepatitis B in HIV-infected patients. J Acquir Immune Defic Syndr 2004; 36: 869875.
  • 51
    Shire NJ, Rouster SD, Stanford SD, Blackard JT, Martin CM, Fichtenbaum CJ, et al. The prevalence and significance of occult hepatitis B virus in a prospective cohort of HIV-infected patients. J Acquir Immune Defic Syndr 2007; 44: 309314.
  • 52
    Neau D, Winnock M, Jouvencel AC, Faure M, Castera L, Legrand E, et al. Occult hepatitis B virus infection in HIV-infected patients with isolated antibodies to hepatitis B core antigen: Aquitaine cohort, 2002-2003. Clin Infect Dis 2005; 40: 750753.
  • 53
    Torbenson M, Kannangai R, Astemborski J, Strathdee SA, Vlahov D, Thomas DL. High prevalence of occult hepatitis B in Baltimore injection drug users. HEPATOLOGY 2004; 39: 5157.
  • 54
    Kao JH, Chen PJ, Lai MY, Chen DS. Occult hepatitis B virus infection and clinical outcomes of patients with chronic hepatitis C. J Clin Microbiol 2002; 40: 40684071.
  • 55
    Sulkowski M, Mehta S, Torbenson M, Moore R, Thomas D. Unexpected significant liver disease among HIV/HCV coinfected persons with minimal fibrosis on initial liver biopsy. Paper presented at: 12th Conference on Retroviruses and Opportunistic Infections; 2005; Boston, MA.
  • 56
    de Ledinghen V, Douvin C, Kettaneh A, Ziol M, Roulot D, Marcellin P, et al. Diagnosis of hepatic fibrosis and cirrhosis by transient elastography in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2006; 41: 175179.
  • 57
    Castera L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, et al. Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology 2005; 128: 343350.
  • 58
    Ziol M, Handra-Luca A, Kettaneh A, Christidis C, Mal F, Kazemi F, et al. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. HEPATOLOGY 2005; 41: 4854.
  • 59
    Branson BM, Handsfield HH, Lampe MA, Janssen RS, Taylor AW, Lyss SB, et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep 2006; 55: 117; quiz CE11–CE14.
  • 60
    Paltiel AD, Walensky RP, Schackman BR, Seage GR III, Mercincavage LM, Weinstein MC, et al. Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. Ann Intern Med 2006; 145: 797806.
  • 61
    Dept of Health and Human Services, Office of AIDS Research Advisory Council. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Available at: http://AIDSinfo.nih.gov. Accessed March 20, 2007.
  • 62
    Hammer SM, Saag MS, Schechter M, Montaner JS, Schooley RT, Jacobsen DM, et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 2006; 296: 827843.
  • 63
    Moore RD, Keruly JC. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis 2007; 44: 441446.
  • 64
    Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner JS. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 × 10(9) cells/L. Ann Intern Med 2003; 139: 810816.
  • 65
    Chung RT, Andersen J, Volberding P, Robbins GK, Liu T, Sherman KE, et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004; 351: 451459.
  • 66
    Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004; 292: 28392848.
  • 67
    Torriani FJ, Rodriguez-Torres M, Rockstroh JK, Lissen E, Gonzalez-Garcia J, Lazzarin A, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 2004; 351: 438450.
  • 68
    Sherman KE, Shire NJ, Rouster SD, Peters MG, James Koziel M, Chung RT, et al. Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients. Gastroenterology 2005; 128: 313327.
  • 69
    Nunez MG-SJ, Romero M, Portu J, Parreiro P, Bonet L, Cordero M, et al. The PRESCO trial: impact of higher ribavirin doses and longer duration of therapy with peginterferon alfa-2a plus ribavirin in HIV-infected patients with chronic hepatitis C. Paper presented at: AASLD, 2006; Boston, MA.
  • 70
    Alvarez D, Dieterich DT, Brau N, Moorehead L, Ball L, Sulkowski MS. Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons. J Viral Hepat 2006; 13: 683689.
  • 71
    Backmund M, Meyer K, Edlin BR. Infrequent reinfection after successful treatment for hepatitis C virus infection in injection drug users. Clin Infect Dis 2004; 39: 15401543.
  • 72
    Edlin BR, Kresina TF, Raymond DB, Carden MR, Gourevitch MN, Rich JD, et al. Overcoming barriers to prevention, care, and treatment of hepatitis C in illicit drug users. Clin Infect Dis 2005; 40( suppl 5): S276S285.
  • 73
    Krogsgaard K, Bindslev N, Christensen E, Craxi A, Schlichting P, Schalm S, et al. The treatment effect of alpha interferon in chronic hepatitis B is independent of pre-treatment variables. Results based on individual patient data from 10 clinical controlled trials. European Concerted Action on Viral Hepatitis (Eurohep). J Hepatol 1994; 21: 646655.
  • 74
    Peters MG, Andersen J, Lynch P, Liu T, Alston-Smith B, Brosgart CL, et al. Randomized controlled study of tenofovir and adefovir in chronic hepatitis B virus and HIV infection: ACTG A5127. HEPATOLOGY 2006; 44: 11101116.
  • 75
    Talal AH, Ribeiro RM, Powers KA, Grace M, Cullen C, Hussain M, et al. Pharmacodynamics of PEG-IFN alpha differentiate HIV/HCV coinfected sustained virological responders from nonresponders. HEPATOLOGY 2006; 43: 943953.
  • 76
    Reisler RB, Han C, Burman WJ, Tedaldi EM, Neaton JD. Grade 4 events are as important as AIDS events in the era of HAART. J Acquir Immune Defic Syndr 2003; 34: 379386.
  • 77
    Walker UA, Setzer B, Venhoff N. Increased long-term mitochondrial toxicity in combinations of nucleoside analogue reverse-transcriptase inhibitors. AIDS 2002; 16: 21652173.
  • 78
    Montessori V, Harris M, Montaner JS. Hepatotoxicity of nucleoside reverse transcriptase inhibitors. Semin Liver Dis 2003; 23: 167172.
  • 79
    Fleischer R, Boxwell D, Sherman KE. Nucleoside analogues and mitochondrial toxicity. Clin Infect Dis 2004; 38: e79e80.
  • 80
    Sulkowski MS, Thomas DL, Chaisson RE, Moore RD. Hepatotoxicity associated with antiretroviral therapy in adults infected with human immunodeficiency virus and the role of hepatitis C or B virus infection. JAMA 2000; 283: 7480.
  • 81
    Sulkowski MS, Mehta SH, Chaisson RE, Thomas DL, Moore RD. Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. AIDS 2004; 18: 22772284.
  • 82
    Deeks SG. Challenges of developing R5 inhibitors in antiretroviral naive HIV-infected patients. Lancet 2006; 367: 711713.
  • 83
    Patel SM, Johnson S, Belknap SM, Chan J, Sha BE, Bennett C. Serious adverse cutaneous and hepatic toxicities associated with nevirapine use by non-HIV-infected individuals. J Acquir Immune Defic Syndr 2004; 35: 120125.
  • 84
    Bessesen M, Ives D, Condreay L, Lawrence S, Sherman KE. Chronic active hepatitis B exacerbations in human immunodeficiency virus-infected patients following development of resistance to or withdrawal of lamivudine. Clin Infect Dis 1999; 28: 10321035.
  • 85
    Schwarz A, Offermann G, Keller F, Bennhold I, L'Age-Stehr J, Krause PH, et al. The effect of cyclosporine on the progression of human immunodeficiency virus type 1 infection transmitted by transplantation—data on four cases and review of the literature. Transplantation 1993; 55: 95103.
  • 86
    High KP. The antimicrobial activities of cyclosporine, FK506, and rapamycin. Transplantation 1994; 57: 16891700.
  • 87
    Heredia A, Amoroso A, Davis C, Le N, Reardon E, Dominique JK, et al. Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV beta-chemokines: an approach to suppress R5 strains of HIV-1. Proc Natl Acad Sci U S A 2003; 100: 1041110416.
  • 88
    Terrault NA, Carter JT, Carlson L, Roland ME, Stock PG. Outcome of patients with hepatitis B virus and human immunodeficiency virus infections referred for liver transplantation. Liver Transpl 2006; 12: 801807.
  • 89
    Berenguer M, Crippin J, Gish R, Bass N, Bostrom A, Netto G, et al. A model to predict severe HCV-related disease following liver transplantation. HEPATOLOGY 2003; 38: 3441.
  • 90
    de Vera ME, Dvorchik I, Tom K, Eghtesad B, Thai N, Shakil O, et al. Survival of liver transplant patients coinfected with HIV and HCV is adversely impacted by recurrent hepatitis C. Am J Transplant 2006; 6: 29832993.
  • 91
    Everson GT, Trotter J, Forman L, Kugelmas M, Halprin A, Fey B, et al. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. HEPATOLOGY 2005; 42: 255262.
  • 92
    Merchante N, Giron-Gonzalez JA, Gonzalez-Serrano M, Torre-Cisneros J, Garcia-Garcia JA, Arizcorreta A, et al. Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease. AIDS 2006; 20: 4957.
  • 93
    Garcia-Samaniego J, Rodriguez M, Berenguer J, Rodriguez-Rosado R, Carbo J, Asensi V, et al. Hepatocellular carcinoma in HIV-infected patients with chronic hepatitis C. Am J Gastroenterol 2001; 96: 179183.
    Direct Link:
  • 94
    Garcia-Garcia JA, Romero-Gomez M, Giron-Gonzalez JA, Rivera-Irigoin R, Torre-Cisneros J, Montero JL, et al. Incidence of and factors associated with hepatocellular carcinoma among hepatitis C virus and human immunodeficiency virus coinfected patients with decompensated cirrhosis. AIDS Res Hum Retroviruses 2006; 22: 12361241.
  • 95
    Murillas J, Del Rio M, Riera M, Vaquer P, Salas A, Leyes M, et al. Increased incidence of hepatocellular carcinoma (HCC) in HIV-1 infected patients. Eur J Intern Med 2005; 16: 113115.
  • 96
    Ragni MV, Eghtesad B, Schlesinger KW, Dvorchik I, Fung JJ. Pretransplant survival is shorter in HIV-positive than HIV-negative subjects with end-stage liver disease. Liver Transpl 2005; 11: 14251430.
  • 97
    Stock PG. Rapid deterioration of HIV co-infected patients waiting for liver transplantation is not predicted by MELD. Liver Transpl 2005; 11: 13151317.
  • 98
    Zucker SD, Qin X, Rouster SD, Yu F, Green RM, Keshavan P, et al. Mechanism of indinavir-induced hyperbilirubinemia. Proc Natl Acad Sci U S A 2001; 98: 1267112676.
  • 99
    Lankisch TO, Moebius U, Wehmeier M, Behrens G, Manns MP, Schmidt RE, et al. Gilbert's disease and atazanavir: from phenotype to UDP-glucuronosyltransferase haplotype. HEPATOLOGY 2006; 44: 13241332.
  • 100
    Huang E, Hewitt RG, Shelton M, Morse GD. Comparison of measured and estimated creatinine clearance in patients with advanced HIV disease. Pharmacotherapy 1996; 16: 222229.
  • 101
    Roland ME, Stock PG. Liver transplantation in HIV-infected recipients. Semin Liver Dis 2006; 26: 273284.